The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Focal therapy using cryoablation for localised stage prostate cancer.
The prostate is a small gland near a man's bladder. Symptoms of localised prostate cancer include difficulties in passing urine, although the disease is often diagnosed before symptoms develop. Focal therapy using freezing (cryotherapy) needles aims to find and destroy only the cancerous part of the prostate, avoiding treatment of healthy tissue. Freezing needles are inserted into the tumour areas, which are then destroyed. The procedure aims to lower the risk of side effects that can occur when radical treatment is given to the whole of the prostate gland (such as loss of bladder control and sexual function).
M70.8 Other specified other operations on outlet of male bladder
Y13.2 Cryotherapy to lesion of organ NOC
Y53.2 Approach to organ under ultrasonic control
In addition the ICD-10 code C61.X Malignant neoplasm of prostate would be recorded.
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new interventional procedures. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Providers should ensure that governance structures are in place to review, authorise and monitor the introduction of new devices and procedures.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.